This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
Growth disorders/growth hormone
Our ambition
We created the world’s first liquid, pre-mixed human growth hormone delivered in a dedicated pen system, Norditropin® SimpleXx®.
Novo Nordisk has been a major player in the field of growth hormone therapy for many decades, and we have world-class expertise in the physiology and pathophysiology of growth and regeneration. We hold a leading position in the global growth hormone market, aiming for a leadership position – and we keep exploring new modalities to treat human growth hormone disorders.
Our partnering focus
We seek technologies and compounds:
- With long-acting potential
- Suitable for oral administration
Read more about Biopharmaceuticals Research Unit
Contact us
For further information please contact Biopharmaceuticals Innovation Sourcing
